BSE · BERLDRG

Beryl Drugs Ltd.

Sector: Healthcare · ISIN: INE415H01017

Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.

Market cap rank

#4,331

of 5,004 stocks

🏆 New peak

▲ 781W

Peak #4,331 · 01 Oct 2026

Beryl Drugs Ltd., a microcap Healthcare business, carries a steep earnings multiple that prices in strong future growth, has a subdued return on equity, and has a widely-held ownership base, with promoters at just 28%. Ownership as of Jun 2026.

Market Cap

13.01 Cr

P/E Ratio

85.50

P/B Ratio

1.32

ROE

4.30%

ROCE

8.94%

Dividend Yield

—

52W High

—

52W Low

—

Quarterly financials

Metric	Q1 2026-27	Q4 2025-26	Q3 2025-26	Q2 2025-26
Revenue	7.30 Cr	5.13 Cr	3.78 Cr	5.12 Cr
Net Profit	22.08 L	56.25 L	-16.77 L	Rs 89,000
EPS	0.44	1.11	0.33	0.02
Operating Profit	33.18 L	93.73 L	-51.61 L	34.05 L

Figures in Cr (crore) unless noted. Source: official company financial disclosures.

Shareholding pattern

Promoter

27.82%

Public

72.18%

PUBLIC BREAKDOWN

Individuals

67.62%

As of 30 Jun 2026. FII, DII, MF & Individuals are sub-categories of Public.

Mutual fund holdings

Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.

Recent corporate actions

Ex-Date	Type	Details
23 Aug 2002	Dividend	NIL Dividend - Rs. - 0.0000

Need this data in your app?

Full price history, technical indicators, and every field above via one REST API call.

View API docs